CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Canada's main stock index opened lower on Monday as investors reined in big bets, kicking off a busy week featuring Ukraine peace talks, a key U.S. central bank conference and domestic inflation data.

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...

Redefining what it means to choose yourself this Women’s Month. Dive deep into her insights on body image, authenticity, and the true meaning of empowerment, and discover how we can bridge the gap ...

Wall Street is holding near its records. The S&P 500 was virtually unchanged Monday, coming off its first loss after setting ...

U.S. stock futures edged lower Monday, while Treasuries gained, as traders focused on progress toward a potential peace deal for Ukraine and awaited signals from the Federal Reserve on interest rates.

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug ...